内容摘要："For me at least, it remains a volatile environment in that sense."

"For me at least, it remains a volatile environment in that sense."

In Wales, more than 2,000 people are diagnosed with breast cancer every year.Capivasertib, which was developed by experts at Velindre Cancer Centre and Cardiff University, became available to breast cancer patients on the NHS in April.

When Ms Buchan's first line of treatment for her terminal breast cancer stopped working, it was a set-back.However, the recent approval of capivasertib for use on the NHS alongside hormone therapy will allow her to enjoy more time with family and friends.She has a common genetic abnormality in her cancer which tests have shown responds well to the drug.

"To be told I had secondary breast cancer but my life can be extended, I think it's that hope you have to keep in your mind," said Ms Buchan from Barry, Vale of Glamorgan."I know that prior to the first line of treatment going down it was expected I'd live five or six years, maybe more.

"The way I cope with this is by thinking about today and today is a good day."

Ms Buchan is among thousands in the UK and millions worldwide who could benefit from the drug.When Ms Buchan's first line of treatment for her terminal breast cancer stopped working, it was a set-back.

However, the recent approval of capivasertib for use on the NHS alongside hormone therapy will allow her to enjoy more time with family and friends.She has a common genetic abnormality in her cancer which tests have shown responds well to the drug.

"To be told I had secondary breast cancer but my life can be extended, I think it's that hope you have to keep in your mind," said Ms Buchan from Barry, Vale of Glamorgan."I know that prior to the first line of treatment going down it was expected I'd live five or six years, maybe more.